Immunic to present additional Phase 2 data on vidofludimus calcium in progressive MSProactive Investors • 02/04/26
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple SclerosisPRNewsWire • 02/04/26
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in DecemberPRNewsWire • 11/26/25
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatePRNewsWire • 11/13/25
Immunic CEO discusses MS focus, upcoming Phase 3 trial readouts - ICYMIProactive Investors • 11/08/25
Immunic targeting mental and physical challenges facing MS patients - ICYMIProactive Investors • 10/11/25
Immunic is aiming for a big breakthrough in the treatment of multiple sclerosisProactive Investors • 09/29/25
Immunic highlights multiple sclerosis drug findings at key neurology gatheringProactive Investors • 09/25/25
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple SclerosisPRNewsWire • 09/25/25
Immunic secures US patent protection for vidofludimus calcium in dose strengths in progressive MSProactive Investors • 09/09/25
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple SclerosisPRNewsWire • 09/09/25
Immunic reports promising Phase 2 data for lead drug candidate in progressive MS - ICYMIProactive Investors • 08/09/25
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatePRNewsWire • 08/07/25